Path To IND For Biologics Delivers Phase I Clinical Trial Material In As Few As 9 Months*

Path to IND is a purpose-built development platform that brings together Thermo Fisher’s deep expertise in biologics development with advanced technologies, proven workflows, and integrated project management. Designed specifically to accelerate the progression of recombinant antibodies from discovery through first-in-human (FIH) studies, the platform streamlines each critical stage of development — from cell line development and process optimization to analytical characterization and GMP manufacturing.

By combining scientific rigor with standardized, risk-mitigated approaches, Path to IND reduces technical uncertainty, shortens timelines, and enhances regulatory readiness. The result is a cohesive, end-to-end solution that enables sponsors to move confidently from early research to clinical evaluation with efficiency, transparency, and speed.